This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujishima, H Articles by Tsubota, K Search for Related Content PubMed PubMed Citation Articles by Fujishima, H Articles by Tsubota, K

Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235

Department of Ophthalmology, Tokyo Dental College and Department of Ophthalmology, Keio University School of Medicine, Japan

Correspondence to:
Correspondence to:
Hiroshi Fujishima, MD, Department of Ophthalmology, Tokyo Dental College, 5-11-13 Sugano, Ichikawa, Chiba, Japan 272-8513;
fujishim{at}tdc.ac.jp

ABSTRACT
Aim: While the mechanism in the pathogenesis of diabetic corneal disease is unclear, aldose reductase has been implicated in corneal disease. The effects of an oral aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients after cataract surgery were studied.

Methods: This clinical trial was designed to be randomised, double blinded, and placebo controlled. Pseudophakic patients with diabetes were randomly assigned to treatment with either oral ARI (ONO-2235) (n=12) or placebo (n=9) for 12 weeks. The vital staining of the ocular surface, tear production and clearance, break up time in tears (BUT), corneal and conjunctival sensation, and symptom score before treatments were examined as well as 4, 8, 12 weeks after the administration. Specular microscopic evaluation was also performed.

Results: After a 12 week period of oral ARI administration, fluorescein staining scores (from 2.04 (SD 1.12) to 1.46 (1.18); p=0.016), conjunctival sensation (from 1.15 (0.37) to 1.36 (0.31); p=0.0006), and symptom scores (from 5.38 (1.932) to 4.00 (2.07); p=0.0002) recovered significantly. Fluorescein staining of oral ARI administration also decreased compared with placebo (p=0.017). Rose bengal staining, tear clearance, and corneal sensation were improved although this increase was minor. Tear production, BUT, and specular microscopic evaluation of the corneal epithelium and endothelium did not demonstrate a significant change.

Conclusion: Oral ARI opposes the ocular surface changes caused by diabetes, by recovery of ocular surface sensitivity as demonstrated through an improvement in vital staining.

Keywords: aldose reductase inhibitor; cataract surgery; diabetes; fluorescein; ocular surface

This article has been cited by other articles:

				V. S. E. Jeganathan, J. J. Wang, and T. Y. Wong Ocular Associations of Diabetes Other Than Diabetic Retinopathy Diabetes Care, September 1, 2008; 31(9): 1905 - 1912. [Full Text] [PDF]

				Y Kaji Prevention of diabetic keratopathy Br. J. Ophthalmol., March 1, 2005; 89(3): 254 - 255. [Full Text] [PDF]

				M Nakahara, K Miyata, S Otani, T Miyai, R Nejima, S Yamagami, and S Amano A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients Br. J. Ophthalmol., March 1, 2005; 89(3): 266 - 268. [Abstract] [Full Text] [PDF]